Immediate Impact
24 standout
Citing Papers
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
2024 Standout
HER2-targeted therapies in cancer: a systematic review
2024 Standout
Works of Michele Bottosso being referenced
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
2022
Evolution of HER2-low expression from primary to recurrent breast cancer
2021
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Michele Bottosso | 345 | 150 | 226 | 30 | 459 | |
| Grazia Maria Vernaci | 392 | 143 | 241 | 24 | 494 | |
| Tommaso Giarratano | 343 | 126 | 216 | 30 | 446 | |
| Christopher Stokoe | 468 | 128 | 249 | 16 | 520 | |
| J-Y Pierga | 370 | 131 | 181 | 52 | 468 | |
| Yayoi Adachi | 291 | 122 | 234 | 42 | 468 | |
| Joanna Niemiec | 238 | 163 | 132 | 44 | 453 | |
| Monica Milano | 303 | 132 | 171 | 21 | 474 | |
| Gabriela Altorjai | 361 | 216 | 81 | 22 | 533 | |
| Yoshikane Nonagase | 376 | 202 | 101 | 19 | 499 | |
| Itai Pashtan | 157 | 146 | 117 | 25 | 483 |
All Works
Login with ORCID to disown or claim papers
Loading papers...